Bristol-Myers Squibb Co. said on May 26 that the FDA granted full approval for its leukemia drug Sprycel (dasatinib). The company had been marketing the drug since 2006 under an accelerated approval, and it is used to treat chronic myeloid leukemia in patients who have not had success with other drugs.